Electronic Supplementary Information

In vitro evidence of oncofetal antigen and TLR-9 agonist co-delivery by alginate nanovaccine for liver cancer immunotherapy

Mengyue Pei\textsuperscript{a,\#}, Huiyang Li\textsuperscript{a,\#}, Yingwei Zhu\textsuperscript{b,\#}, Jian Lu\textsuperscript{c}, Chuangnian Zhang\textsuperscript{a,\#}

\textsuperscript{a} Tianjin Key Laboratory of Biomaterial Research, Biomedical Barriers Research Center, Institute of Biomedical Engineering, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, 300192, China

\textsuperscript{b} Department of Gastroenterology, The Affiliated Wuxi No.2 People’s Hospital of Nanjing Medical University, Wuxi city, 214002, China

\textsuperscript{c} Department of Gastroenterology, Wuxi No.2 People’s Hospital, Affiliated Wuxi Clinical College of Nantong University, Wuxi city, 214002, China

\textsuperscript{d} State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, 300353, China

\# Mengyue Pei and Huiyang Li contributed equally to this work.

* Corresponding authors

Dr. Yingwei Zhu, zhuyingw2020@163.com;

Dr. Chuangnian Zhang, cnzhang@mail.nankai.edu.cn;
Supplemental figures

Figure S1. The chemical structure of GPC-3_{127-136} peptide (AMFKNNYPSL).

Figure S2. CLSM image of Hepa1-6 cells.

Figure S3. The total IgG level in mice serum.
Figure S4. The body weight during the total immunization course.